Therapeutic Effect of Imatinib Made in Real World to Newly Diagnosed Chronic Myeloid Leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 456-461, 2021.
Article
in Zh
| WPRIM
| ID: wpr-880097
Responsible library:
WPRO
ABSTRACT
OBJECTIVE@#To evaluate the clinical efficacy and safety of domestic imatinib (made in China) in patients with newly diagnosed chronic myeloid leukemia chronic phase(CML-CP).@*METHODS@#Fifty-seven newly diagnosed CML-CP patients who did not receive any other anti-CML treatment were treated by domestic imatinib 400 mg once a day. The hematological, cytogenetic and molecular reactions and safety were observed and evaluated after 3, 6 and 12 months of treatment.@*RESULTS@#Fifty-six patients were treated for ≥3 and 6 months, among which 50 patients were treated for ≥12 months. After 3 months of treatment, 49 patients underwent hematological examination, 47 patients (95.9%) achieved complete hematological response (CHR), 49 patients underwent cytogenetic examination, 39 patients (79.6%) achieved major cytogenetic response (MCyR), and 12 patients (24.5%) achieved complete cytogenetic response (CCyR). 49 patients underwent the level of BCR-ABL test, including 41 patients (83.7%) with BCR-ABL@*CONCLUSION@#In the real world, Domestics imatinib mesylate is effective and safe in the treatment of newly diagnosed CML-CP patients, but long-term follow-up data are still necessary to verify its long-term efficacy.
Full text:
1
Index:
WPRIM
Main subject:
Piperazines
/
Pyrimidines
/
Benzamides
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
China
/
Fusion Proteins, bcr-abl
/
Treatment Outcome
/
Imatinib Mesylate
/
Antineoplastic Agents
Limits:
Humans
Country/Region as subject:
Asia
Language:
Zh
Journal:
Journal of Experimental Hematology
Year:
2021
Type:
Article